Regeneron Pharmaceuticals Inc said on Tuesday initial data from an ongoing study of its experimental antibody cocktail for use in some hospitalized COVID19 patients show the therapy was sufficiently effective to warrant continuing the trial.
from Top World News- News18.com https://ift.tt/3hqCwkS
via Click here
from Top World News- News18.com https://ift.tt/3hqCwkS
via Click here
Comments
Post a Comment